MedTrace Logo

Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer

NCT01717482 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn whether it is better to receive the drug Metformin with standard of care for lung cancer or just standard of care.

Conditions

  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Metformin

OTHER

Placebo Comparator

Standard of Care Observation

Sponsors & Collaborators

  • Alliance for Clinical Trials in Oncology

    collaborator OTHER

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Dennis Wigle, MD, PhD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2019-05-22
Completion
2019-05-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01717482 on ClinicalTrials.gov